Romain BUISSON/LinkedIn
Nov 5, 2025, 05:14
Penumbra Announces Secondary Results of the Ground-Breaking STORM – PE RCT
Romain Buisson, Country Manager (TH-HK cluster) at Penumbra, Inc., shared a post by Penumbra, Inc. on LinkedIn:
”Latest updates in STORM PE
Patient treated with CAVT plus anticoagulation experienced significantly longer distance walked during the 90-day six-minute walk test (472m vs 376m; P = 0.019).
CAVT patients near normalized by 90 days, walking 94% of their predicted walk distance vs 75% in the anticoagulation only arm (P = 0.022)”
Quoting Penumbra, Inc.’s post:
”Penumbra announces secondary results of the ground-breaking STORM-PE RCT at VIVA 2025. Read more here.”
Stay updated with Hemostasis Today.
-
Sep 22, 2026, 13:15Suvro Sankha Datta: Developing Blood Group Genotyping Platform Using a Gold-Oligo
-
Sep 22, 2026, 13:07Caitlin Raymond: The Plasma Chaser in Therapeutic Plasma Exchange
-
Sep 22, 2026, 09:18Shamee Shastry: How Transfusion Medicine Research Is Evolving in India
-
Sep 22, 2026, 09:11Tarique Shahzad Chachar: Why Warfarin Remains the Gold Standard for Mechanical Heart Valves
-
Sep 22, 2026, 09:04Bianca Rocca: Thromboinflammatory Injury in Ischemic Limb Necrosis During Severe Shock
-
Sep 22, 2026, 09:01Ash Paul: Comparing Left Atrial Appendage Occlusion and Oral Anticoagulation
-
Sep 22, 2026, 08:50Emily Horner: Lipoprotein(a) Links Oxidized Phospholipids to Platelet Hyperactivity
-
Sep 22, 2026, 08:42Sally Mandour: Bone Marrow Needle Gauge Explained
-
Sep 22, 2026, 08:39Alessandro Sionis: Navigating Anticoagulation in Mechanical Circulatory Support